Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1CNS 1

Conditions

Multiple Myeloma 444Lymphoma 55Recurrence 44Neoplasms, Plasma Cell 35Immunoglobulin Light-chain Amyloidosis 34Hematologic Neoplasms 34Smoldering Multiple Myeloma 28Lymphoma, Non-Hodgkin 26Leukemia, Myeloid, Acute 22Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Hodgkin Disease 18Myelodysplastic Syndromes 17Monoclonal Gammopathy of Undetermined Significance 13Leukemia 12Waldenstrom Macroglobulinemia 11Lymphoma, Mantle-Cell 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Breast Neoplasms 11Prostatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Paraproteinemias 9Ovarian Neoplasms 9Amyloidosis 9Lung Neoplasms 8Leukemia, Plasma Cell 8Primary Myelofibrosis 7Melanoma 7Lymphoma, Follicular 7

Interventions

selinexor 1pazopanib 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myoepithelioma × Plasma cell × 90 days × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡